Oxidative stress as a major culprit in kidney disease in diabetes

被引:1360
作者
Forbes, Josephine M. [1 ,2 ,3 ]
Coughlan, Melinda T. [1 ]
Cooper, Mark E. [1 ,2 ,3 ]
机构
[1] Baker Heart Res Inst, Albert Einstein Ctr Diabet Complicat, Div Diabet & Metab, Juvenile Diabet Res Fdn, Melbourne, Vic 8008, Australia
[2] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia
[3] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia
关键词
D O I
10.2337/db08-0057
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
It is postulated that localized tissue oxidative stress is a key component in the development of diabetic nephropathy. There remains controversy, however, as to whether this is an early link between hyperglycemia and renal disease or develops as a consequence of other primary pathogenic mechanisms. In the kidney, a number of pathways that generate reactive oxygen species (ROS) such as glycolysis, specific defects in the polyol pathway, uncoupling of nitric oxide synthase, xanthine oxidase, NAD(P)H oxidase, and advanced glycation have been identified as potentially major contributors to the pathogenesis of diabetic kidney disease. In addition, a unifying hypothesis has been proposed whereby mitochondrial production of ROS in response to chronic hyperglycemia may be the key initiator for each of these pathogenic pathways. This postulate emphasizes the importance of mitochondrial dysfunction in the progression and development of diabetes complications including nephropathy. A mystery remains, however, as to why antioxidants per se have demonstrated minimal renoprotection in humans despite positive preclinical research findings. It is likely that the utility of current study approaches, such as vitamin use, may not be the ideal antioxidant strategy in human diabetic nephropathy. There is now an increasing body of data to suggest that strategies involving a more targeted antioxidant approach, using agents that penetrate specific cellular compartments, may be the elusive additive therapy required to further optimize renoprotection in diabetes.
引用
收藏
页码:1446 / 1454
页数:9
相关论文
共 61 条
[1]
Effects of NADPH oxidase inhibitor in diabetic nephropathy [J].
Asaba, K ;
Tojo, A ;
Onozato, ML ;
Goto, A ;
Quinn, MT ;
Fujita, T ;
Wilcox, CS .
KIDNEY INTERNATIONAL, 2005, 67 (05) :1890-1898
[2]
Double-edged action of SOD mimetic in diabetic nephropathy [J].
Asaba, Kensuke ;
Tojo, Akihiro ;
Onozato, Maristela Lika ;
Goto, Atsuo ;
Fujita, Toshiro .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 49 (01) :13-19
[3]
Recombinant insulin-like growth factor I normalizes expression of renal glucose transporters in diabetic rats [J].
Asada, T ;
Ogawa, T ;
Iwai, M ;
Shimomura, K ;
Kobayashi, M .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1997, 273 (01) :F27-F37
[4]
Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice [J].
Brezniceanu, M.-L. ;
Liu, F. ;
Wei, C.-C. ;
Tran, S. ;
Sachetelli, S. ;
Zhang, S.-L. ;
Guo, D.-F. ;
Filep, J. G. ;
Ingelfinger, J. R. ;
Chan, J. S. D. .
KIDNEY INTERNATIONAL, 2007, 71 (09) :912-923
[5]
Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy [J].
Ceriello, A ;
Morocutti, A ;
Mercuri, F ;
Quagliaro, L ;
Moro, M ;
Damante, G ;
Viberti, GC .
DIABETES, 2000, 49 (12) :2170-2177
[6]
Choi Ki Chul, 1999, Korean Journal of Internal Medicine, V14, P32
[7]
Pathogenesis, prevention, and treatment of diabetic nephropathy [J].
Cooper, ME .
LANCET, 1998, 352 (9123) :213-219
[8]
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: Synergy or redundancy? [J].
Coughlan, Melinda T. ;
Thallas-Bonke, Vicki ;
Pete, Josefa ;
Long, David M. ;
Gasser, Anna ;
Tong, David C. K. ;
Arnstein, Maryann ;
Thorpe, Suzanne R. ;
Cooper, Mark E. ;
Forbes, Josephine M. .
ENDOCRINOLOGY, 2007, 148 (02) :886-895
[9]
The human glomerular podocyte is a novel target for insulin action [J].
Coward, RJM ;
Welsh, GI ;
Yang, J ;
Tasman, C ;
Lennon, R ;
Koziell, A ;
Satchell, S ;
Holman, GD ;
Kerjaschki, D ;
Tavaré, JM ;
Mathieson, PW ;
Saleem, MA .
DIABETES, 2005, 54 (11) :3095-3102
[10]
Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy [J].
de Haan, JB ;
Stefanovic, N ;
Nikolic-Paterson, D ;
Scurr, LL ;
Croft, KD ;
Mori, TA ;
Hertzog, P ;
Kola, I ;
Atkins, RC ;
Tesch, GH .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2005, 289 (03) :F544-F551